NURIX THERAPEUTICS INC. - COMMON STOCK

Nurix Therapeutics to Participate in Upcoming Investor Conferences

04 мар 2025 04:00:01 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 фев 2025 13:01:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

04 фев 2025 04:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

28 янв 2025 13:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

22 янв 2025 04:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases

13 янв 2025 04:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

06 янв 2025 04:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

19 дек 2024 04:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

09 дек 2024 15:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

02 дек 2024 04:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

25 ноя 2024 04:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

20 ноя 2024 13:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

05 ноя 2024 06:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

31 окт 2024 04:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

21 окт 2024 13:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia

19 окт 2024 05:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

16 окт 2024 13:35:41 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

11 окт 2024 13:00:28 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology

09 окт 2024 04:00:00 Источник Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at Discovery on Target Conference

30 сен 2024 04:00:00 Источник Nasdaq GlobeNewswire